Age equal to or greater than 18 years old.Willingness to perform a self-collect nose/throat swab.Willingness to inform the study nurse/co-ordinator of COVID-19 testing.Signed written and verbal informed consent.
#SEQUENTIAL MULTIPLE ASSIGNMENT RANDOMIZED TRIAL TRIAL#
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)ĬOVID-19 Prevention and Treatment in Cancer a Sequential Multiple Assignment Randomised Trial C-SMART Study. (sequential multiple arm randomised trial) meaning that participants can enter into the study and progress through the subsequent arms if they meet the additional eligibility criteria (for instance, pre-covid > post exposure > develop moderate infection > infection becomes severe) it is important to note that participants can enter into the study at any point and do not have to transition into the other arms Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information Condition or diseaseĬancer Covid19 Respiratory Viral Infectionĭrug: Interferon alfa Drug: Selinexor Drug: Lenzilumab It is hoped this research will provide insight into the best practice for prevention and treatment of COVID-19 in cancer patients as emerging standard of care measures are not always suitable to this especially vulnerable population. Participants may become eligible and transition to different arms and treatments if they become exposed to COVID-19 or are hospitalised with an active moderate/severe COVID-19 infection. Why Should I Register and Submit Results?Ī multi-centre Australian trial with four arms aims to evaluate several different immune modulating drugs for prevention and treatment of COVID-19 specifically in the cancer population.ĪRM 1 is evaluating the effect of interferon-alpha (vs placebo) on the incidence of COVID-19 infection in cancer patients with no COVID-19 infection or no known COVID-19 positive contacts.ĪRM 2 is evaluating the effect of interferon-alpha (vs placebo) on the incidence of COVID-19 infection in cancer patients with confirmed exposure to COVID-19 virus.ĪRM 3 is evaluating the effect of Selinexor (vs placebo) on the incidence of COVID-19 infection in cancer patients with moderate COVID-19 infection.ĪRM 4 is evaluating the effect of Lenzilumab (vs placebo) on the treatment of COVID-19 infection in cancer patients with severe COVID-19 infection.
0 kommentar(er)
